What We Have Learned From Adjuvant Therapy for Resected EGFR-Mutant Non–Small-Cell Lung Cancer

Abstract

Author affiliations and support information (if applicable) appear at the end of this article.

Meta-Analysis of Rates and Risk Factors for Local Recurrence in Surgically Resected Patients With NSCLC and Differences Between Asian and Non-Asian Populations

“… 11 Because we would assume that the definition of LR in this trial would at least include the mediastinum, ipsilateral hilum, and ipsilateral lung, we believe that the difference between these two trials would be magnified if recurrences were just restricted to the mediastinum. Nevertheless, it should be noted that the nature of NSCLC is different in AP than NAP, largely because of differences in EGFR mutation (EGFRmut) frequency, which were found to be present in 47% (range 20%–76%) of adenocarcinomas in the AP as compared with 15% 4 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 and 22% 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , …”

Recent Advances in Adjuvant Therapy for Non–Small-Cell Lung Cancer

“…OS was also not different (HR, 1.03; 95% CI, 0.65 to 1.65), with the 5-year OS rates being 78.0% and 74.6% in the gefitinib and cisplatin/vinorelbine groups, respectively [ 17 ]. This negative evidence for first-generation adjuvant TKI highlights the importance of drug choice and therapy duration in this setting [ 21 ].…”

Expert consensus on treatment for stage III non‐small cell lung cancer

“…The decision‐making of adjuvant therapy should focus on the exploration of a more precise treatment model, that is, precisely screening the patients who will benefit and exploring the most appropriate treatment duration to improve the cure rate of resectable NSCLC [22]. Because EGFR ‐mutated NSCLC at the early stage has a high molecular heterogeneity, biomarker prediction is needed to determine the individualized adjuvant therapy.…”